Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The Terasaki Innovation Center currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These filings are split between multiple distinct examiners and 2 distinct art units. This suggests that the center's research and development efforts are branching into different specialized niches within the biotechnology sector.
Examiner MONTGOMERY, ANN Y is the busiest examiner for the center, holding 1 pending office action. With multiple distinct examiners each handling a single pending office action, the workload is evenly distributed across the portfolio's current USPTO footprint. This distribution means that the progress of the portfolio is not dependent on the schedule or tendencies of a single examiner.
The involvement of 2 distinct art units for the pending actions suggests a lack of examiner overlap. This requires the center to navigate different procedural nuances and examination standards across the separate art units involved in their prosecution. Effectively managing the pending office actions will involve tailored strategies for each specific art unit and examiner combination.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTGOMERY, ANN Y | 1 | 69.1% | +27.6% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264013 | METHODS AND MATERIALS FOR IMPROVED IMMUNOASSAYS USING SYNTHETIC ANTIGENS | HOWARD, ZACHARY C | 70d |
| 18435898 | IMMUNOLOGICAL METHODS INVOLVING DRA:DQB AND DPA:DQB HETERODIMERS | MONTGOMERY, ANN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264013 | METHODS AND MATERIALS FOR IMPROVED IMMUNOASSAYS USING SYNTHETIC ANTIGENS | HOWARD, ZACHARY C | 70d |
| 18435898 | IMMUNOLOGICAL METHODS INVOLVING DRA:DQB AND DPA:DQB HETERODIMERS | MONTGOMERY, ANN Y | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18435898 | IMMUNOLOGICAL METHODS INVOLVING DRA:DQB AND DPA:DQB HETERODIMERS | MONTGOMERY, ANN Y | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18264013 | METHODS AND MATERIALS FOR IMPROVED IMMUNOASSAYS USING SYNTHETIC ANTIGENS | HOWARD, ZACHARY C | 1674 | §102§103§112 | Final Rejection | 70d | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Terasaki Innovation Center has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ann Y Montgomery has the most, with 1 of The Terasaki Innovation Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
